选择语言

FITC-Labeled Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc)

用户评价
货号-规格
价格
Qty.

CD0-CF2H3-20ug
¥14700.00

CD0-CF2H3-100ug
¥54600.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    MS4A1, CD20, MS4A-1

  • 表达区间及表达系统(Source)

    FITC-Labeled Cynomolgus CD20 Full Length Protein, His Tag (CD0-CF2H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1 ).

    Predicted N-terminus: Met 1

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa.

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by an amphipathic scaffold coat that confers enhanced stability and a narrow particle size distribution.

    The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein upon removal of the detergent.

  • 偶联(Conjugate)

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • 标记(Labeling)

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

  • 纯度(Purity)

    >85% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储(Storage)

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程
  • *The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.

推荐产品

数据展示

  • 活性(Bioactivity)-ELISA

     CD20 ELISA

    Immobilized FITC-Labeled Cynomolgus CD20 Full Length Protein, His Tag (Cat. No. CD0-CF2H3) at 2 μg/mL (100 μL/well) can bind Rituximab biosimilar with a linear range of 0.01-0.156 μg/mL (QC tested).

    Protocol

用户评价
发表评论

背景介绍

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

前沿进展

 
药物研发进展
  • 英文全称:

    B-lymphocyte antigen CD20

  • 中文全称:

    B淋巴细胞抗原CD20

  • 种类:

  • 上市药物数量:

    33 详情

  • 临床药物数量:

    108 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍